Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Expert Opinion / Conference Coverage · November 19, 2013

TCT: New Trial Data on DAPT Duration Following 2nd Generation Stents

 

Additional Info

  1. Feres F, Costa RA, Abizaid A, et al, for the OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents. The OPTIMIZE randomized trial. JAMA. 2013; published online October 31, 2013.

  2. Scirica BM, Bonaca MP, Braunwald E, et al, for the TRA 2°P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI Investigators. Lancet. 2012;38:1317-1324.

  3. Bhatt DL, Foxx KAA, Hacke W, et al, for the CHARISMA Investigators. Clopidogrel plus aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.

Disclosure statements are available on the authors' profiles:

Further Reading